We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Mail Order Mifepristone Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03913104
Recruitment Status : Active, not recruiting
First Posted : April 12, 2019
Last Update Posted : July 11, 2022
Information provided by (Responsible Party):
Daniel Grossman, MD, University of California, San Francisco

Brief Summary:
This study aims to evaluate the feasibility, acceptability, and effectiveness of dispensing mifepristone via a mail-order pharmacy. The investigators will recruit patients at up to 10 primary care and internal medicines sites not currently providing abortion services around the country, as well as abortion clinic sites. Patients will go through routine in clinic visits to determine eligibility and then will receive the medications in the mail at their preferred address. The investigators will survey patients 3 and 14 days after the initial clinic visit and interview providers at the end of the study.

Condition or disease Intervention/treatment Phase
Abortion Early Pregnancy Related Drug: Mifepristone Phase 4

Detailed Description:
This is a prospective cohort study of patients obtaining medication abortion via mifepristone dispensed from an online mail order pharmacy. After an initial pilot test with 25 patients, the investigators will identify 10 clinics to participate in the study. The study team will train primary care providers not currently providing abortion to provide medication abortion with the medications dispensed via mail order pharmacy. The investigators aim to recruit up to 650 patients for this study across all the sites. Patients will come in for an initial consult visit at the study site and then receive their medications at a preferred address within 3 days of the initial visit. Study participants will fill out surveys about their experience and feedback about the acceptability of the process; this will occur at 3 and 14 days after the initial recruitment visit. The investigators will also collect clinic data from patients and clinic sites to track clinical outcomes. And the investigators will interview providers at the end of the study to better understand their experiences prescribing mifepristone via mail-order.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 538 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective Cohort
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy
Actual Study Start Date : January 5, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Medication Abortion Patients
Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
Drug: Mifepristone
Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.

Primary Outcome Measures :
  1. Proportion of patients who report positive experience. [ Time Frame: Day 14 following initial medication abortion visit ]
    Proportion of patients reporting whether they would use the mail order service again if they needed another abortion.

Secondary Outcome Measures :
  1. Proportion of patients who report timely delivery of medication. [ Time Frame: Day 3 following initial medication abortion visit ]
    Proportion of patients who receive medications by Day 2 and Day 3 and proportion of patients who indicate their confidentiality was maintained when receiving medications by mail. The investigators will also estimate the proportion of patients who report that medications were lost, stolen or damaged.

  2. Proportion of patients who have a complete abortion [ Time Frame: Up to 6 weeks after initial medication abortion visit. ]
    Using electronic health record data related to abortion, the investigators will estimate the proportion of patients who experience a complete abortion and the proportion of patients who experience complications, including adverse or severe adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women seeking medication abortion through 63 days gestation
  • Eligible for MifeprexⓇ at a study site
  • English or Spanish speaking
  • Willing and able to participate in the study, including willing and able to receive medications at home or other preferred address within 3 days of initial medication abortion visit

Exclusion Criteria:

  • Not pregnant
  • Not seeking medication abortion
  • under the age of 15
  • Over 63 days gestation
  • Contraindicated for medication abortion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913104

Layout table for location information
United States, California
Highland Hospital
Oakland, California, United States, 94602
Children's Hospital Oakland
Oakland, California, United States, 94609
United States, Colorado
Planned Parenthood Rocky Mountains
Denver, Colorado, United States, 80218
United States, Delaware
Christiana Care Health System
Wilmington, Delaware, United States, 19899
United States, Georgia
Atlanta Comprehensive Wellness Clinic
Atlanta, Georgia, United States, 30324
United States, New York
Albert Einstein College of Medicine
New York, New York, United States, 10461
Southern Tier Women's Health Services
Vestal, New York, United States, 13850
United States, Pennsylvania
Delaware County Women's Center
Chester, Pennsylvania, United States, 19013
Allegheny Reproductive Health Center
Pittsburgh, Pennsylvania, United States, 15206
United States, Rhode Island
Brown Family Medicine
Pawtucket, Rhode Island, United States, 02860
Providence, Rhode Island, United States, 02905
Sponsors and Collaborators
Daniel Grossman, MD
Layout table for investigator information
Principal Investigator: Daniel Grossman, MD University of California, San Francisco
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Daniel Grossman, MD, Professor and Director of ANSIRH, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03913104    
Other Study ID Numbers: 18-26819
First Posted: April 12, 2019    Key Record Dates
Last Update Posted: July 11, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Contraceptive Agents, Hormonal
Menstruation-Inducing Agents